Top entities: Amgen, United States — Food and Drug Administration, United States — California State Board of Pharmacy.

What category does this event fall under?

Regulatory — classified as medication recall.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

What were the key actions taken?

Amgen recalled bottles · United States — Food and Drug Administration assigned risk level

Is this event still developing?

This is an active story, last updated Jun 30, 2026. Coverage continues to evolve.

Regulatory medication recall

Amgen Recalls Corlanor, Sensipar Tablets

Q: When did this event occur?

First reported Jun 27, 2026; last updated Jun 30, 2026.

Q: What is the market impact?

General. The recall by Amgen of nearly one million bottles of Corlanor and Sensipar tablets could lead to a temporary dip in investor confidence in Amgen, although the low health risk assessment might mitigate long-term stock price impact.

Analysis based on 7 articles · First reported Jun 27, 2026 · Last updated Jun 30, 2026

Sentiment

-20

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The recall by Amgen of nearly one million bottles of Corlanor and Sensipar tablets could lead to a temporary dip in investor confidence in Amgen, although the low health risk assessment might mitigate long-term stock price impact. The pharmaceutical industry may face increased scrutiny regarding manufacturing processes, but the overall market impact is expected to be contained given the specific nature of the recall.

pharmaceuticals

Event Summary

Amgen has voluntarily recalled nearly one million bottles of its heart medication Corlanor and kidney medication Sensipar nationwide. The recall was initiated after an 'unexpected foreign matter' was found on the exterior tablet surface of a reserve sample. The United States — Food and Drug Administration has classified this as a Class II recall, indicating a low probability of serious adverse health consequences. The United States — California State Board of Pharmacy also issued an alert regarding the recall. Despite the recall, hazard assessments suggest a low clinical risk to patients, and no complaints have been reported. The affected tablets were distributed between October 28, 2021, and December 30, 2025.

Key Actions

100 Amgen recalled bottles

70 United States — Food and Drug Administration assigned risk level

Entities Involved

stock

Amgen

Amgen voluntarily recalled nearly one million bottles of its Corlanor and Sensipar tablets due to the presence of a foreign substance, impacting its product distribution and potentially its reputation, though the health risk is deemed low.

Importance 100.0 Sentiment -20.0

govactor

United States — Food and Drug Administration

The United States — Food and Drug Administration characterized the medication recall as Class II and is overseeing the recall process initiated by Amgen, ensuring public safety and regulatory compliance.

Importance 80.0 Sentiment 0.0

govactor

United States — California State Board of Pharmacy

The United States — California State Board of Pharmacy issued an alert regarding Amgen's recall of Corlanor and Sensipar tablets, providing details on the foreign matter and the precautionary measures taken.

Importance 60.0 Sentiment 0.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard